Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer

Chemotherapy

Volumn 56, Issue 2, 2010, Pages 142-146

  Roca, José María ^a   Alonso, Vicente ^b   Pericay, Carles ^c   Escudero, Pilar ^d   Salud, Antonieta ^e   Losa, Ferrán ^f   López, Luis Jesús ^g   Guasch, Imma ^h   Méndez, Miguel ⁱ   Quintero Aldana, Guillermo ^j   Grande, Carlos ^k   Vicente, Pilar ^l   Arrivi, Antonio ^m   Martin, Cristina ⁿ   Moreno, Isabel ^o   García, Pilar ^p   Antón, Isabel ^q   Constenla, Manuel ^r   Yubero, Alfonso ^s   Cirera, Luis ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL DE SABADELL   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^f Hospital General de l'Hospitalet   (Spain)

^g HOSPITAL VIRGEN DE LA SALUD   (Spain)

^h Althaia   (Spain)

ⁱ Hospital Ernest Lluch   (Spain)

^j HOSPITAL XERAL CALDE   (Spain)

^k HOSPITAL DO MEIXOEIRO   (Spain)

^l HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^m HOSPITAL SON LLÀTZER   (Spain)

ⁿ HOSPITAL DE L ESPERIT SANT   (Spain)

^o Hospital Municipal de Badalona   (Spain)

^p HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^q Hospital Sant Jaume de Calella   (Spain)

^r HOSPITAL MONTECELO   (Spain)

^s HOSPITAL OBISPO POLANCO   (Spain)

more..

Author keywords

Cetuximab; Colorectal cancer; Irinotecan; Metastasis

Indexed keywords

CETUXIMAB; IRINOTECAN;

ACNE; ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 77952253032     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313527     Document Type: Article

References (20)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
3. Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M: Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A singleinstitution outcome study. Chemotherapy 2008; 54: 395-403.
4. Sadahiro S, Suzuki T, Maeda Y, Ishikawa K, Yasuda S, Makuuchi H, Murayama C: Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer. Chemotherapy 2008; 54: 140-146.
5. National Cancer Institute, US National Institutes of Health: Colon cancer treatment (PDQ- ). http://www.cancer.gov/cancertopics/ pdq/treatment/colon/ healthprofessional.
6. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras Mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
8. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastasic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
10. Tabernero J, Pfeiffer P, Cervantes A: Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008; 13: 113-119.
11. Tabernero J, Cervantes A, Martinelli E, Vega-Villegas E, Rojo F, Pérez-Fidalgo A, Casado E, Ciardiello F, Zubel A, Baselga J: Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) (abstract 3085). J Clin Oncol 2006; 24(suppl):18s.
12. Ciardiello F, Cervantes A, Vega-Villegas M, Casado E, Rodriguez-Braun E, Martinelli E, Rojo F, Baselga J, Kisker O, Tabernero J: Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules. Eur J Cancer 2007(suppl 5):247.
13. Pfeiffer P, Bjerregaard JK, Qvortrup C, Jensen BV, Yilmaz M, Nielsen D: Simplification of cetuximab (Cet) administration: double dose every second week as a 60 minute infusion (abstract 4133). J Clin Oncol 2007; 25(suppl):18s.
14. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B: Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19: 1141-1145.
15. Martín-Martorell P, Roselló S, Rodríguez-Braun E, Chirivella I, Bosch A, Cervantes A: Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008; 99: 455-458.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
17. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1959; 53: 457-481.
18. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ: Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536-3544.
19. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004; 22: 4772-4778.
20. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.